137 related articles for article (PubMed ID: 8132440)
41. Fluvoxamine versus fluoxetine in major depressive episode: a double-blind randomised comparison.
Dalery J; Honig A
Hum Psychopharmacol; 2003 Jul; 18(5):379-84. PubMed ID: 12858325
[TBL] [Abstract][Full Text] [Related]
42. The oral dose-effect relationship for fluvoxamine: a fixed-dose comparison against placebo in depressed outpatients.
Walczak DD; Apter JT; Halikas JA; Borison RL; Carman JS; Post GL; Patrick R; Cohn JB; Cunningham LA; Rittberg B; Preskorn SH; Kang JS; Wilcox CS
Ann Clin Psychiatry; 1996 Sep; 8(3):139-51. PubMed ID: 8899132
[TBL] [Abstract][Full Text] [Related]
43. Sulpiride and paroxetine in the treatment of chronic tension-type headache. An explanatory double-blind trial.
Langemark M; Olesen J
Headache; 1994 Jan; 34(1):20-4. PubMed ID: 8132436
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. The LUCIFER Group.
Haffmans PM; Timmerman L; Hoogduin CA
Int Clin Psychopharmacol; 1996 Sep; 11(3):157-64. PubMed ID: 8923094
[TBL] [Abstract][Full Text] [Related]
45. Serotonin precursors in chronic primary headache. A double-blind cross-over study with L-5-hydroxytryptophan vs. placebo.
De Benedittis G; Massei R
J Neurosurg Sci; 1985; 29(3):239-48. PubMed ID: 3913752
[TBL] [Abstract][Full Text] [Related]
46. A comparison of fluvoxamine and fluoxetine in the treatment of major depression.
Rapaport M; Coccaro E; Sheline Y; Perse T; Holland P; Fabre L; Bradford D
J Clin Psychopharmacol; 1996 Oct; 16(5):373-8. PubMed ID: 8889909
[TBL] [Abstract][Full Text] [Related]
47. Amitriptyline in the treatment of headache in patients with Parkinson's disease: a double-blind placebo-controlled study.
Indaco A; Carrieri PB
Neurology; 1988 Nov; 38(11):1720-2. PubMed ID: 3054626
[TBL] [Abstract][Full Text] [Related]
48. A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression.
Otsubo T; Akimoto Y; Yamada H; Koda R; Aoyama H; Tanaka K; Mimura M; Nakagome K; Kamijima K
Pharmacopsychiatry; 2005 Jan; 38(1):30-5. PubMed ID: 15706464
[TBL] [Abstract][Full Text] [Related]
49. Selective serotonin reuptake inhibitors for migraine prophylaxis.
Landy S; McGinnis J; Curlin D; Laizure SC
Headache; 1999 Jan; 39(1):28-32. PubMed ID: 15613191
[TBL] [Abstract][Full Text] [Related]
50. Fluvoxamine versus imipramine and placebo: a double-blind comparison in depressed patients.
Fabre L; Birkhimer LJ; Zaborny BA; Wong LF; Kapik BM
Int Clin Psychopharmacol; 1996 Jun; 11(2):119-27. PubMed ID: 8803649
[TBL] [Abstract][Full Text] [Related]
51. Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors.
Grimsley SR; Jann MW
Clin Pharm; 1992 Nov; 11(11):930-57. PubMed ID: 1464219
[TBL] [Abstract][Full Text] [Related]
52. Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline.
Waldinger MD; Hengeveld MW; Zwinderman AH; Olivier B
J Clin Psychopharmacol; 1998 Aug; 18(4):274-81. PubMed ID: 9690692
[TBL] [Abstract][Full Text] [Related]
53. Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study.
Zheng H; Jia F; Han H; Wang S; Guo G; Quan D; Li G; Huang H
Eur Neuropsychopharmacol; 2019 Mar; 29(3):397-404. PubMed ID: 30595354
[TBL] [Abstract][Full Text] [Related]
54. Onset of clinical effects and plasma concentration of fluvoxamine in Japanese patients.
Katoh Y; Uchida S; Kawai M; Takei N; Mori N; Kawakami J; Kagawa Y; Yamada S; Namiki N; Hashimoto H
Biol Pharm Bull; 2010; 33(12):1999-2002. PubMed ID: 21139240
[TBL] [Abstract][Full Text] [Related]
55. Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness.
Wilde MI; Plosker GL; Benfield P
Drugs; 1993 Nov; 46(5):895-924. PubMed ID: 7507038
[TBL] [Abstract][Full Text] [Related]
56. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial.
Goodman WK; Kozak MJ; Liebowitz M; White KL
Int Clin Psychopharmacol; 1996 Mar; 11(1):21-9. PubMed ID: 8732310
[TBL] [Abstract][Full Text] [Related]
57. A double-blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder.
van Vliet IM; den Boer JA; Westenberg HG; Slaap BR
J Clin Psychopharmacol; 1996 Aug; 16(4):299-306. PubMed ID: 8835705
[TBL] [Abstract][Full Text] [Related]
58. Two items on the Hamilton Depression rating scale are effective predictors of remission: comparison of selective serotonin reuptake inhibitors with the combined serotonin/norepinephrine reuptake inhibitor, venlafaxine.
Silverstone PH; Entsuah R; Hackett D
Int Clin Psychopharmacol; 2002 Nov; 17(6):273-80. PubMed ID: 12409680
[TBL] [Abstract][Full Text] [Related]
59. A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder: a high placebo response.
Pearlstein T; Spurell E; Hohlstein LA; Gurney V; Read J; Fuchs C; Keller MB
Arch Womens Ment Health; 2003 Apr; 6(2):147-51. PubMed ID: 12720065
[TBL] [Abstract][Full Text] [Related]
60. Short-term single-blind fluvoxamine treatment of pathological gambling.
Hollander E; DeCaria CM; Mari E; Wong CM; Mosovich S; Grossman R; Begaz T
Am J Psychiatry; 1998 Dec; 155(12):1781-3. PubMed ID: 9842795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
